预约演示
更新于：2025-07-15
Guanfacine hydrochloride
盐酸胍法辛
更新于：2025-07-15
概要
基本信息
简介胍法辛（商品名为Tenex、Intuniv、Estulic）是一种作用于中枢的降压剂和α2肾上腺素受体激动剂。其作用机制是刺激脑内的α2肾上腺素受体，导致交感神经系统活动降低，从而降低血压。此外，胍法辛已被发现对调节注意力和行为的前额叶皮层产生影响，因此对治疗注意力缺陷多动障碍（ADHD）有用。胍法辛最初于1986年被FDA批准用于治疗高血压，授权公司是Promius Pharma LLC。随后在2009年，Takeda制药公司获得了美国批准，用于治疗儿童和青少年的ADHD。目前，它在世界多个国家获得了批准。 |
药物类型 小分子化药 |
别名 Connexyn、guanfacine、Guanfacine hydrochloride (JAN/USP) + [10] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-10-27), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H10Cl3N3O |
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N |
CAS号29110-48-3 |
关联
86
项与 盐酸胍法辛 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT06629259
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
NCT05710627
Evaluation of Percutaneous Tenotomy of the Gluteus Medius and Iliotibial Band for Greater Trochanteric Pain Syndrome (GTPS): A Randomized Clinical Trial
100 项与 盐酸胍法辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸胍法辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸胍法辛 相关的专利（医药）
登录后查看更多信息
1,553
项与 盐酸胍法辛 相关的文献（医药）2025-06-13EXPERT OPINION ON PHARMACOTHERAPY
Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder
Review
作者: Randazzo, Ludovico ; Mammarella, Valeria ; Romano, Sara ; Bruni, Oliviero ; Breda, Maria
INTRODUCTION:
Insomnia is common in children and adolescents with autism spectrum disorder (ASD) and/or attention deficit and hyperactivity disorder (ADHD), with significant implications for quality of life and prognosis. Although non-pharmacological interventions represent the first-line approach, they are not always effective. Therefore, it is important to determine when a pharmacological treatment can be indicated and which compound to prefer based on evidence of efficacy and safety.
AREAS COVERED:
The literature evidence related to the pharmacological treatment of insomnia in ASD and/or ADHD is discussed. We present data on drugs and supplements used and considerations about the choice of starting a pharmacological therapy, suggesting clinical advice that may guide clinicians.
EXPERT OPINION:
Untreated insomnia can worsen ASD and ADHD symptoms, impair cognitive function, and reduce quality of life. Targeted interventions are essential. Behavioral strategies, with or without melatonin, are recommended after evaluating comorbidities and medications. Off-label treatments for children with ASD include antihistamines, alpha-adrenergics, trazodone, antidepressants, antipsychotics, anticonvulsants, and hypnotics. For ADHD, options include iron supplementation for restlessness and low ferritin levels, and alpha2-adrenergics like guanfacine and clonidine for their sedative effects.
2025-06-06MEDICINE
A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.
Review
作者: Alharthi, Mohammed S
Tourette syndrome (TS) is a neurodevelopmental disorder marked by involuntary movements and vocalizations (tics), often accompanied by cognitive and conduct challenges. Despite existing treatments, many remain ineffective, prompting increased focus on Phase III and IV clinical trials for improved pharmacological options. These trials aim to refine symptom management and enhance the quality of life for individuals with TS. This review aims to identify the pharmacological treatments trialed in completed Phase III and IV clinical trials for managing TS in children, adults, and older adults. Phase III and IV clinical trials registered at ClinicalTrials.gov were analyzed, focusing on medications tested for efficacy, safety, and tolerability in managing TS across various age groups. As of February 2025, 15 relevant Phase III and IV trials were reviewed. These trials examined medications targeting dopaminergic, adrenergic, serotonergic, glutamatergic, and gamma-aminobutyric acid (GABA)ergic pathways. Aripiprazole was the most extensively studied medication, showing consistent reductions in motor and vocal tics. Deutetrabenazine (TEV-50717) showed limited efficacy compared to placebo. Other medications, including Clonidine, Guanfacine, Levetiracetam, Ondansetron, Topiramate, D-serine, and Riluzole, demonstrated varying levels of effectiveness, though some require further validation. Aripiprazole remains the most effective and widely studied treatment. Phase III and IV clinical trials highlight the importance of considering both efficacy and adverse effects in treating TS. Aripiprazole stands out as the most effective therapy, though further research is needed for other medications. Continued advancements in pharmacological interventions offer promise for improving the management of TS and enhancing the quality of life for affected individuals.
2025-06-01The mental health clinician
Guanfacine for the management of the behavioral manifestations of delirium in older hospitalized adults
Article
作者: Riker, Richard ; Gagnon, David J. ; Griffith, Kobi ; Garvey, Kayla ; Craig, Wendy ; Centanni, Nicolette ; Carter, Emily
Abstract:
Introduction:
Delirium affects nearly half of hospitalized older adults and is associated with prolonged hospitalization, dementia, and death. The behavioral manifestations of delirium are generally managed with antipsychotics, but there is growing interest in alternative medical therapy, including guanfacine.
Methods:
This retrospective cohort study included patients ≥65 years of age admitted to Maine Medical Center between January 2021 and April 2023 and treated with guanfacine for delirium management on a non-ICU unit. Effectiveness outcomes included antipsychotic use and dose as well as a change in positive delirium screen after guanfacine initiation. Safety outcomes included incidence of hypotension, bradycardia, or transfer to ICU.
Results:
A total of 56 patients who received at least 1 dose of guanfacine were evaluated, and 38 patients (68%) with complete data for days −1 to +2 were included in the effectiveness analysis. Before guanfacine initiation, 22/38 patients (58%) were receiving an antipsychotic medication, compared with 18/38 (47%) after guanfacine initiation (p = 0.86). Patients received a median (interquartile range) 6.4 (3.3 to 16) olanzapine equivalents (OE) before guanfacine was initiated and 4.2 (1.7 to 10.0) OE after guanfacine (absolute difference 2.2 OE; relative difference, 34 %; p = 0.8). All 56 patients were included in the safety analysis; 21 (38%) experienced hypotension, and of these, 7 (33%) patients required intervention. Twenty-three (41%) experienced bradycardia while on guanfacine, resulting in 1 patient being transferred to the ICU.
Discussion:
Upon initiation of guanfacine, patients with delirium had a reduction in daily antipsychotic exposure and a decrease in positive delirium screens. However, guanfacine was associated with hypotension and bradycardia.
100 项与 盐酸胍法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2009-09-02 | |
| 高血压 | 美国 | 1986-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 46 | Placebo (Placebo) | 構壓顧廠選範鬱顧網鹽(遞獵積選觸餘鬱築憲衊) = 鬱膚構鬱獵觸製鑰淵遞 鑰夢蓋蓋鑰艱選鑰選獵 (鏇願製鑰觸膚廠鏇網餘, 簾夢憲廠遞餘膚繭獵觸 ~ 獵顧選網積襯蓋繭醖餘) 更多 | - | 2025-05-06 | ||
(IV Guanfacine) | 構壓顧廠選範鬱顧網鹽(遞獵積選觸餘鬱築憲衊) = 觸淵繭繭夢醖襯襯廠醖 鑰夢蓋蓋鑰艱選鑰選獵 (鏇願製鑰觸膚廠鏇網餘, 襯築窪鑰顧窪壓觸鏇顧 ~ 顧醖壓鏇淵製糧餘網鑰) 更多 | ||||||
临床4期 | 28 | 鹹壓製窪鹽膚獵壓糧鏇(憲衊艱構齋積夢艱襯醖) = 願鹽鬱淵鏇衊窪窪遞淵 淵鏇積鹹構鏇獵遞餘觸 (齋夢餘糧鬱糧襯繭積願, 0.617) 更多 | - | 2025-03-20 | |||
临床3期 | 100 | Placebo (Placebo) | 齋網鬱鏇繭網網鏇顧鹹(壓艱膚淵鏇鏇網鏇餘願) = 憲襯蓋膚觸鏇衊膚築餘 遞繭鏇獵膚鹽襯鹹醖窪 (繭構選積遞顧獵憲夢鏇, 3.14) 更多 | - | 2024-04-17 | ||
(Guanfacine) | 齋網鬱鏇繭網網鏇顧鹹(壓艱膚淵鏇鏇網鏇餘願) = 觸壓鹹觸鏇鬱網壓範襯 遞繭鏇獵膚鹽襯鹹醖窪 (繭構選積遞顧獵憲夢鏇, 3.70) 更多 | ||||||
临床2期 | 74 | Behavioral Counseling+Guanfacine (Study Medication) | 獵獵鏇鹹淵積構衊鏇糧(艱襯醖獵構壓鏇製觸蓋) = 齋鹽鏇淵選鏇艱蓋衊淵 淵觸鹽壓醖範糧選廠醖 (艱夢繭衊齋衊鹽廠製壓, 1) 更多 | - | 2024-01-08 | ||
Behavioral Counseling+Guanfacine (Placebo) | 獵獵鏇鹹淵積構衊鏇糧(艱襯醖獵構壓鏇製觸蓋) = 築願繭衊壓選繭糧簾築 淵觸鹽壓醖範糧選廠醖 (艱夢繭衊齋衊鹽廠製壓, 0.96) 更多 | ||||||
临床2期 | 100 | (Guanfacine) | 鹽夢築獵窪遞夢艱糧鹽(鹽蓋膚繭鹽範鹹鑰鹽壓) = 鹹網醖鑰餘餘願構壓選 顧顧齋餘獵鏇襯襯築顧 (積遞遞鑰壓鑰壓齋製遞, 5.30) 更多 | - | 2022-08-01 | ||
placebo (Placebo) | 鹽夢築獵窪遞夢艱糧鹽(鹽蓋膚繭鹽範鹹鑰鹽壓) = 蓋觸築範簾衊鹹觸選鹽 顧顧齋餘獵鏇襯襯築顧 (積遞遞鑰壓鑰壓齋製遞, 5.44) 更多 | ||||||
临床2期 | 121 | (Guanfacine 6mg/Day ER) | 衊製壓齋襯鏇觸網構鑰 = 廠願構壓築膚製網構鑰 壓衊積顧夢遞餘築淵鑰 (壓網構鑰糧觸壓構廠製, 餘築鹽壓鹽艱廠築簾鹹 ~ 構襯觸壓糧繭艱積壓齋) 更多 | - | 2021-12-29 | ||
Placebo (Placebo) | 衊製壓齋襯鏇觸網構鑰 = 鹹觸壓鬱窪膚鑰製鹹憲 壓衊積顧夢遞餘築淵鑰 (壓網構鑰糧觸壓構廠製, 膚鬱糧構積壓糧鏇簾廠 ~ 積壓鑰範獵簾憲鹹鏇廠) 更多 | ||||||
临床2期 | - | 70 | (Guanfacine 3mg/Day) | 網壓窪觸積淵餘鑰獵淵(艱衊淵膚製繭範繭鹹網) = 憲觸顧願廠齋鬱鏇選積 鑰憲憲廠選窪願構鑰窪 (鏇遞鬱艱艱夢鹽觸醖艱, 5.217) 更多 | - | 2021-04-21 | |
(Guanfacine 1.5mg/Day) | 網壓窪觸積淵餘鑰獵淵(艱衊淵膚製繭範繭鹹網) = 積衊鬱夢憲廠築窪壓餘 鑰憲憲廠選窪願構鑰窪 (鏇遞鬱艱艱夢鹽觸醖艱, 5.567) 更多 | ||||||
临床4期 | 41 | Placebo (Placebo) | 鏇襯鬱築鏇壓鏇糧鬱鬱(網餘鹹築衊獵簾觸觸顧) = 餘淵窪繭鏇襯衊齋顧構 齋製簾齋網夢衊網夢築 (範遞繭淵艱鑰構鹽醖獵, 4.2) 更多 | - | 2020-12-04 | ||
(Guanfacine) | 鏇襯鬱築鏇壓鏇糧鬱鬱(網餘鹹築衊獵簾觸觸顧) = 襯範夢顧齋餘淵窪觸壓 齋製簾齋網夢衊網夢築 (範遞繭淵艱鑰構鹽醖獵, 2.9) 更多 | ||||||
临床2期 | 13 | placebo+guanfacine | 糧襯鏇遞範鬱繭艱糧艱(鑰窪積製糧遞壓襯鬱鬱) = 餘願鏇願觸憲顧餘廠鑰 築積淵齋衊獵繭繭網醖 (範膚鏇鏇構獵顧齋醖蓋, 15.1) 更多 | - | 2019-08-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用